VYEPTI
Biological
H. Lundbeck A S
Total Payments
$15.7M
Transactions
81,194
Doctors
15,675
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3.5M | 27,717 | 8,330 |
| 2023 | $3.7M | 21,867 | 7,311 |
| 2022 | $2.3M | 17,056 | 6,518 |
| 2021 | $2.0M | 10,148 | 4,141 |
| 2020 | $4.3M | 4,406 | 1,694 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.1M | 1,476 | 51.6% |
| Honoraria | $4.0M | 1,697 | 25.5% |
| Food and Beverage | $1.8M | 74,284 | 11.3% |
| Consulting Fee | $1.3M | 1,925 | 8.1% |
| Travel and Lodging | $534,737 | 1,736 | 3.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,664 | 13 | 0.1% |
| Education | $360.26 | 63 | 0.0% |
Payments by Type
Research
$8.1M
1,476 transactions
General
$7.6M
79,718 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Evaluate Efficacy & Safety of Eptinezumab Administered Intravenously in Subjects Experiencing Acute Attack of Migraine (RELIEF) | H. Lundbeck A S | $3.4M | 0 |
| A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) | H. Lundbeck A S | $945,001 | 0 |
| A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) | H. Lundbeck A S | $809,127 | 0 |
| A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE | H. Lundbeck A S | $599,425 | 0 |
| A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) | H. Lundbeck A S | $584,139 | 0 |
| INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE | H. Lundbeck A S | $542,116 | 0 |
| EPTINEZUMAB IN PARTICIPANTS WITH EPISODIC CLUSTER HEADACHE (ALLEVIATE) | H. Lundbeck A S | $226,936 | 0 |
| A STUDY IN CHILDREN AND YOUNG PEOPLE WITH MIGRAINE TO LEARN WHAT THE BODY DOES TO EPTINEZUMAB | H. Lundbeck A S | $218,693 | 0 |
| INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | H. Lundbeck A S | $200,943 | 0 |
| A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) | H. Lundbeck A S | $196,267 | 0 |
| A STUDY OF EPTINEZUMAB IN PARTICIPANTS WITH MIGRAINE AND MEDICATION OVERUSE HEADACHE | H. Lundbeck A S | $139,799 | 0 |
| REAL WORLD EFFECTIVENESS OF EPTINEZUMAB IN PARTICIPANTS WITH MIGRAINE (EVEC) | H. Lundbeck A S | $116,753 | 0 |
| Retrospective analysis of subcutaneous injection calcitonin gene-related peptide receptor antagonist switches to intravenous eptinezumab for the preventive treatment of migraine | H. Lundbeck A S | $95,000 | 0 |
| Real-world Evidence and Insights into Experiences With Vyepti (REVIEW- Vyepti) | H. Lundbeck A S | $27,735 | 0 |
| A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS THAT ARE NOT HELPED BY PREVIOUS PREVENTIVE TREATMENTS (DELIVER) | H. Lundbeck A S | $15,170 | 0 |
| Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine (PROMISE 2) | Lundbeck LLC | $7,587 | 0 |
| A pregnancy exposure registry to assess the maternal, fetal and infant safety of exposure to eptinezumab during pregnancy | H. Lundbeck A S | $6,583 | 0 |
Top Doctors Receiving Payments for VYEPTI — Page 626
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D., | Neurology | Edmond, OK | $11.89 | 1 |
| , PA-C | Physician Assistant | Johnson City, TN | $11.89 | 1 |
| , M.D | Family Medicine | Lakewood, CO | $11.84 | 1 |
| , D.O | Family Medicine | Colorado Springs, CO | $11.84 | 1 |
| , PA-C | Physician Assistant | Lakewood, CO | $11.84 | 1 |
| , F.N.P | Family | Lakewood, CO | $11.84 | 1 |
| , MD | Family Medicine | Greenville, SC | $11.84 | 1 |
| Raymond Ryan | — | Knoxville, TN | $11.81 | 1 |
| Tommi Haidet | Family | Alliance, OH | $11.78 | 1 |
| , MD, PHD | Neurological Surgery | Boston, MA | $11.77 | 1 |
| Anna Kavanaugh | Family | Newburgh, IN | $11.76 | 1 |
| , FNP | Family | Newburgh, IN | $11.76 | 1 |
| , M.D., PHD | Family Medicine | Newburgh, IN | $11.76 | 1 |
| , MD | Physical Medicine & Rehabilitation | Lufkin, TX | $11.75 | 1 |
| , MD | Neurology | Lufkin, TX | $11.75 | 1 |
| , NP | Family | Boise, ID | $11.74 | 1 |
| , MD | Allergy & Immunology | Boise, ID | $11.74 | 1 |
| , PA | Physician Assistant | Keller, TX | $11.73 | 1 |
| , P.A.-C | Physician Assistant | Keller, TX | $11.73 | 1 |
| , M.D | Internal Medicine | Watertown, MA | $11.72 | 1 |
| , M.D | Family Medicine | Beckley, WV | $11.71 | 1 |
| , P.A | Medical | Beckley, WV | $11.71 | 1 |
| , D.O | Family Medicine | Beckley, WV | $11.71 | 1 |
| , FNP-C | Family | Amarillo, TX | $11.65 | 1 |
| , APRN | Family | Newport, TN | $11.65 | 1 |
Ad
Manufacturing Companies
- H. Lundbeck A S $9.2M
- Lundbeck LLC $6.5M
Product Information
- Type Biological
- Total Payments $15.7M
- Total Doctors 15,675
- Transactions 81,194
About VYEPTI
VYEPTI is a biological associated with $15.7M in payments to 15,675 healthcare providers, recorded across 81,194 transactions in the CMS Open Payments database. The primary manufacturer is H. Lundbeck A S.
Payment data is available from 2020 to 2024. In 2024, $3.5M was paid across 27,717 transactions to 8,330 doctors.
The most common payment nature for VYEPTI is "Unspecified" ($8.1M, 51.6% of total).
VYEPTI is associated with 17 research studies, including "Evaluate Efficacy & Safety of Eptinezumab Administered Intravenously in Subjects Experiencing Acute Attack of Migraine (RELIEF)" ($3.4M).